Bluejay Diagnostics (NASDAQ:BJDX) Major Shareholder Financial Lp Hrt Buys 64,047 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt acquired 64,047 shares of the stock in a transaction on Thursday, July 9th. The shares were bought at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the purchase, the insider directly owned 126,993 shares of the company’s stock, valued at $191,759.43. The trade was a 101.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock. The shares were sold at an average price of $1.40, for a total value of $48,913.20.

Bluejay Diagnostics Stock Down 15.9%

Shares of BJDX opened at $1.22 on Tuesday. Bluejay Diagnostics, Inc. has a 52-week low of $1.03 and a 52-week high of $16.68. The stock has a fifty day simple moving average of $2.68 and a two-hundred day simple moving average of $2.48. The company has a market capitalization of $1.26 million, a PE ratio of -0.10 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.